Vitality Watch

⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.

Mentioned 9× · first seen 09-sep-2026 · last seen 10-nov-2026

CAR T Cells as Living Senolytics

Current understanding

Chimeric antigen receptor (CAR) T cells engineered against surface antigens enriched on senescent cells (e.g., uPAR, NKG2D ligands) are being proposed as a ‘living’ senolytic modality with potentially more specific and durable clearance than small-molecule senolytics like dasatinib+quercetin or fisetin. Current support is preclinical: mouse studies show reversal of liver fibrosis and improved metabolic parameters after single dosing [animal-model], plus target-discovery and engineering reviews framing the paradigm [expert-opinion]. No human efficacy data in aging indications yet; oncology-derived safety concerns (cytokine release, on-target/off-tumor toxicity) transfer directly.

Evidence log

Open questions

Related

Contributing findings

pubmed review expert-opinion
Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.
09-nov-2026 novelty 3 per-area 3 strengthens
pubmed review
Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.
09-oct-2026 novelty 3 per-area 2 mentions
pubmed preclinical animal-model
uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
01-oct-2026 novelty 4 per-area 4 strengthens
rss preclinical
uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor
29-sep-2026 novelty 4 per-area 4 strengthens
pubmed review expert-opinion
Autologous cytokine-induced NK cells as candidate cellular senolytics: evidence, obstacles, and the experiments still needed.
29-sep-2026 novelty 3 per-area 3 strengthens
pubmed review
Senolytics for Cancer treatment: complexities and opportunities.
23-sep-2026 novelty 2 per-area 3 mentions
pubmed review
Multidimensional Regulatory Network of Cellular Senescence: From Mechanisms to Theranostics.
15-sep-2026 novelty 2 per-area 3 strengthens
rss expert media
How Your Immune System Works & How to Improve It | Dr. Max Krummel
03-aug-2026 novelty 2 per-area 2 mentions
pubmed review
Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases.
12-jun-2026 novelty 3 per-area 3 introduces

build build 880 · 2bcef25 · 2026-11-18